| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 5. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | budesonide / formoterol fumarate dihydrate (Fobumix Easyhaler®) |
| Formulation | 80 micrograms/4.5 micrograms, 160 micrograms/4.5 micrograms and 320 micrograms/9 micrograms dry powder inhaler |
| Reference number | 3477 |
| Indication | In adults aged 18 years and older for the regular treatment of asthma where use of a combination (inhaled corticosteroid and longacting β2 adrenoceptor agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists or - patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists. Note: Fobumix Easyhaler 80 micrograms/ 4.5 micrograms is not appropriate in patients with severe asthma |
| Company | Orion Pharma (UK) Ltd |
| BNF chapter | Respiratory system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 05/04/2017 |